News Releases

Pfenex Names Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer

SAN DIEGO, September 11, 2018 —Pfenex Inc. (NYSE American: PFNX) today announced that Dr. Shawn A. Scranton, will be joining Pfenex as its Chief Operating Officer, effective October 1, 2018.

"As our operations have evolved through the advancement of our clinical pipeline and Pfenex is working towards its first NDA submission, we are increasing our focus on the approval and commercialization of our existing pipeline as well as exploration of new pipeline and technology opportunities. I am excited to announce the appointment of Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer, who will support this transition to a commercial stage biotech company" said Eef Schimmelpennink, Chief Executive Officer of Pfenex. "Shawn brings more than 20 years of experience in the biopharmaceutical industry, including a breadth
of accomplishments in portfolio strategy, pharmaceutical research, clinical development, and commercial operations."

Dr. Scranton previously served as Chief Scientific Officer at Sentynl Therapeutics, Inc., a private specialty pharmaceutical company, recently acquired by Zydus Cadila. Prior to Sentynl, Dr. Scranton served as the Vice President of Scientific Operations at Victory Pharma, Inc, where he oversaw Clinical Development, Regulatory, Manufacturing and Medical Affairs functions, while managing the pipeline development programs. Prior to Victory, Dr. Scranton was Senior Director of Translational Medicine for Kalypsys, Inc., where he contributed to non-clinical, regulatory, and clinical strategies that enabled the successful opening of two INDs and
conducting Phase 1 clinical programs for two new chemical entities (NCE) in neuropathic pain and metabolic disease.

"I am excited to join the Pfenex team at this important time in the Company’s development," said Dr. Scranton. "I look forward to working with the rest of the management team to execute upon its exciting pipeline of programs to generate significant stockholder value." 

Cautionary Note Regarding Forward-Looking Statement – This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Pfenex's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions that concern Pfenex's future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding potential new pipeline and technology opportunities, Pfenex’s future plans to develop, advance, and seek regulatory approval for its product candidates; Pfenex’s
anticipated NDA submission; and Pfenex’s anticipated transition to a commercial stage company. Pfenex's expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Actual results may differ materially from those indicated by these forward-looking statements as a result of the uncertainties inherent in the clinical drug development process, including, without limitation, Pfenex's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates or may require Pfenex to conduct additional clinical trials or modify ongoing clinical trials or regulatory pathways; challenges related to commencement, patient enrollment, completion, and analysis of clinical trials; difficulties in achieving and demonstrating biosimilarity in formulations; Pfenex's ability to manage operating expenses; Pfenex's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives; Pfenex's dependence on third parties for development, manufacture, marketing, sales and distribution of products; unexpected expenditures; litigation and other proceedings regarding intellectual property rights, including potential future litigation by Eli Lilly and Company with respect to PF708; and difficulties in obtaining and maintaining intellectual property protection for its product candidates. Information on these and additional risks, uncertainties, and other information affecting Pfenex's business and operating results is contained in Pfenex’s Quarterly Report on Form 10-Q for the period ended June 30, 2018 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Pfenex as of the date hereof, and Pfenex disclaims any obligation to update any forward-looking statements, except as required by law. Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (, our investor relations website (, press releases, SEC filings, public conference calls, corporate Twitter account (, Facebook page (, and LinkedIn page ( in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.

We are a clinical-stage development and licensing biotechnology company focused on leveraging our Pfēnex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfēnex Expression Technology platform, we have created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Our lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and our novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, we are developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.

Company Contact:
Susan A. Knudson
Chief Financial Officer
(858) 352-4324

Subscribe to our Investor Alerts
* Required Fields